Literature on the use of PD‐1 inhibitors in rhabdomyosarcoma is limited to one trial of combination therapy with PD‐1 and CTLA‐4 inhibitors, which found a clinically significant sustained partial response in 1 of 7 pediatric patients with alveolar rhabdomyosarcoma [13]. This evidence concerns the gene CTLA4 and rhabdomyosarcoma.